Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
tideglusib glycogen synthase kinase-3 beta small molecule Clinical trial target TTD , drugbank , DGIDB Amyloidosis[MeSHID:D000686]
Brain[MeSHID:D001921]
Transcriptional Activation[MeSHID:D015533]
Disease[MeSHID:D004194]
Cessation of life[MeSHID:D003643]
Progressive supranuclear palsy[MeSHID:D013494]
Cell Survival[MeSHID:D002470]
Up-Regulation (Physiology)[MeSHID:D015854]
Precipitating Factors[MeSHID:D015985]
Neurons[MeSHID:D009474]
Transcription
Genetic[MeSHID:D014158]
Dental caries[MeSHID:D003731]
Wound Healing[MeSHID:D014945]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Osteosarcoma[MeSHID:D012516]		 3.06 investigational,withdrawn,phase 2 antagonist,inhibitor
tideglusib glycogen synthase kinase-3 beta small molecule Clinical trial target TTD , drugbank , DGIDB Amyloidosis[MeSHID:D000686]
Brain[MeSHID:D001921]
Transcriptional Activation[MeSHID:D015533]
Disease[MeSHID:D004194]
Cessation of life[MeSHID:D003643]
Progressive supranuclear palsy[MeSHID:D013494]
Cell Survival[MeSHID:D002470]
Up-Regulation (Physiology)[MeSHID:D015854]
Precipitating Factors[MeSHID:D015985]
Neurons[MeSHID:D009474]
Transcription
Genetic[MeSHID:D014158]
Dental caries[MeSHID:D003731]
Wound Healing[MeSHID:D014945]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]		 3.06 investigational,withdrawn,phase 2 antagonist,inhibitor
tideglusib glycogen synthase kinase-3 beta small molecule Clinical trial target TTD , drugbank , DGIDB Amyloidosis[MeSHID:D000686]
Brain[MeSHID:D001921]
Transcriptional Activation[MeSHID:D015533]
Disease[MeSHID:D004194]
Cessation of life[MeSHID:D003643]
Progressive supranuclear palsy[MeSHID:D013494]
Cell Survival[MeSHID:D002470]
Up-Regulation (Physiology)[MeSHID:D015854]
Precipitating Factors[MeSHID:D015985]
Neurons[MeSHID:D009474]
Transcription
Genetic[MeSHID:D014158]
Dental caries[MeSHID:D003731]
Wound Healing[MeSHID:D014945]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Osteosarcoma[MeSHID:D012516]		 3.06 investigational,withdrawn,phase 2 antagonist
tideglusib glycogen synthase kinase-3 beta small molecule Clinical trial target TTD , drugbank , DGIDB Amyloidosis[MeSHID:D000686]
Brain[MeSHID:D001921]
Transcriptional Activation[MeSHID:D015533]
Disease[MeSHID:D004194]
Cessation of life[MeSHID:D003643]
Progressive supranuclear palsy[MeSHID:D013494]
Cell Survival[MeSHID:D002470]
Up-Regulation (Physiology)[MeSHID:D015854]
Precipitating Factors[MeSHID:D015985]
Neurons[MeSHID:D009474]
Transcription
Genetic[MeSHID:D014158]
Dental caries[MeSHID:D003731]
Wound Healing[MeSHID:D014945]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Coronavirus Infections[MeSHID:D018352]		 3.06 investigational,withdrawn,phase 2 antagonist
click here to return to the previous page